Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10780407 | 0.84 | KDM4E (0.32) | KDM4ETSHRCYP1A2CYP2C19HSD17B10 | |
| SCHEMBL27656919 | 0.74 | — | — | |
| SCHEMBL27976239 | 0.74 | TSHR (0.33) | KDM4EALDH1A1TSHRNT5ECYP1A2 | |
| SCHEMBL9395961 | 0.74 | CYP1A2 (0.36) | KDM4EALDH1A1TSHRNT5ECYP1A2 | |
| SCHEMBL27764568 | 0.72 | — | — | |
| SCHEMBL29065907 | 0.72 | TSHR (0.59) | KDM4EBCL6ALDH1A1TSHRNT5E | |
| Water SCHEMBL6716218 | 0.71 | — | — | |
| SCHEMBL11407198 | 0.69 | LMNA (0.33) | CYP1A2SMN1; SMN2 | |
| SCHEMBL8020815 | 0.69 | — | — | |
| Octane SCHEMBL28223647 | 0.69 | ALDH1A1 (0.38) | KDM4EALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1155582-C | Process for the preparation of 2-amino-4-chloro-1, 3, 5-triazines | �Ϻ���ͨ��ѧ | 2004-06-30 | — | — | CN | claimed |
| CN-1306518-A | Process for the preparation of 2-amino-4-chloro-1, 3, 5-triazines | AVENTIES CROPS SCIENCES GMBH (DE) | 2001-08-01 | — | — | CN | claimed |
| JP-57133192-A | — | — | None | — | — | JP | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11077095-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-1155582-C | Process for the preparation of 2-amino-4-chloro-1, 3, 5-triazines | �Ϻ���ͨ��ѧ | 2004-06-30 | — | — | CN | disclosed |
| CN-1137108-C | Fluorinated triazine monomers | — | 2004-02-04 | — | — | CN | disclosed |
| CN-1306518-A | Process for the preparation of 2-amino-4-chloro-1, 3, 5-triazines | AVENTIES CROPS SCIENCES GMBH (DE) | 2001-08-01 | — | — | CN | disclosed |
| CN-1271350-A | Fluorinated triazine monomers | SECR DEFENCE (GB) | 2000-10-25 | — | — | CN | disclosed |
| US-4470828-A | INCLUDING A MODIFIED POLYETHER AND A SULFONATED ANIONIC SURFACTANT; FLUID FLOW; ANTISTATIC AGENTS | KAO CORPORATION (JP) | 1984-09-11 | — | — | US | disclosed |
| JP-S57133192-A | DISPERSANT FOR POWDERY COAL-WATER SLURRY | KAO CORP | 1982-08-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077095-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | KDM4E 3838/4885HSP90AA1 305/4885BCL6 1887/4885 |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | KDM4E 3838/4885HSP90AA1 305/4885BCL6 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.